Patents Examined by Agnieszka Boesen
-
Patent number: 11969466Abstract: Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.Type: GrantFiled: May 8, 2023Date of Patent: April 30, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John R. Mascola, Jeffrey C. Boyington, Hadi M. Yassine, Peter D. Kwong, Barney S. Graham, Masaru Kanekiyo
-
Patent number: 11964006Abstract: Disclosed are vaccine compositions comprising a VLP comprising two or more EBV envelope glycoproteins and one or more T cell antigens and methods of preventing or treating EBV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more EBV envelope glycoproteins simultaneously to generate a VLP vaccine. The expression system may include a single vector inserted with two or more nucleic acid sequences that encode two or more EBV envelope glycoproteins linked by one or more linking sequences such that the EBV envelope glycoproteins are co-expressed simultaneously.Type: GrantFiled: September 16, 2018Date of Patent: April 23, 2024Assignee: CITY OF HOPEInventors: Javier Gordon Ogembo, Lorraine Zvichapera Mutsvunguma, Felix Wussow
-
Patent number: 11965000Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.Type: GrantFiled: September 7, 2023Date of Patent: April 23, 2024Assignee: CureVac SEInventors: Thomas Kramps, Margit Schnee, Daniel Voss, Benjamin Petsch
-
Patent number: 11932681Abstract: The present invention relates to anti-HBsAg antibodies, antibody fragments, and their uses for the prevention and treatment of hepatitis B virus infection and associated diseases.Type: GrantFiled: May 30, 2019Date of Patent: March 19, 2024Assignee: Novartis AGInventors: Stefan Ewert, Meghan Marie Holdorf, Elisabetta Traggiai
-
Patent number: 11932879Abstract: This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.Type: GrantFiled: June 23, 2022Date of Patent: March 19, 2024Assignee: Mayo Foundation for Medical Education and ResearchInventors: Mark J. Federspiel, Arun Ammayappan, Gennett Pike, Stephen James Russell
-
Patent number: 11905320Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.Type: GrantFiled: May 26, 2023Date of Patent: February 20, 2024Assignee: Cue Biopharma, Inc.Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
-
Patent number: 11896662Abstract: Disclosed herein are multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles include effective amounts of influenza glycoproteins that provide increased immune responses compared to a commercially available influenza vaccine composition. The present disclosure also provides vaccine formulation strategies that are cost effective and are convenient for clinical use. Methods of administering the nanoparticle vaccine compositions to a subject are also disclosed.Type: GrantFiled: November 24, 2021Date of Patent: February 13, 2024Assignee: Novavax, Inc.Inventors: Sarathi Boddapati, Anushree Herwadkar, Jason Wong, Yen-Huei Lin, Gale Smith, Jing-Hui Tian
-
Patent number: 11865080Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: January 9, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11866463Abstract: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition. The invention also relates to antibodies to composite antigens of the invention and to methods of administering vaccines comprising antigens or vaccines of antibodies for treating and/or preventing an infection.Type: GrantFiled: January 29, 2021Date of Patent: January 9, 2024Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Luke T. Daum, Gerald W. Fischer, Clara J. Sei
-
Patent number: 11857562Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: January 2, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11851467Abstract: The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.Type: GrantFiled: December 13, 2022Date of Patent: December 26, 2023Assignee: Cue Biopharma, Inc.Inventors: Ronald D. Seidel, III, Rodolfo J. Chaparro
-
Patent number: 11845787Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an HIV antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an HIV infection in a subject using said composition and method of generation.Type: GrantFiled: March 27, 2018Date of Patent: December 19, 2023Assignees: The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.Inventors: David Weiner, Megan Wise
-
Patent number: 11839650Abstract: The present application generally relates to the development of a universal influenza vaccine, or production of antibodies, capable of providing broad protection against various strains of the flu, using an informational spectrum method (ISM) to identify the common structural characteristics of influenza antigens.Type: GrantFiled: February 2, 2018Date of Patent: December 12, 2023Assignee: Board of Regents, The University of Texas SystemInventors: Veljko Veljkovic, Slobodan Paessler
-
Patent number: 11834649Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.Type: GrantFiled: April 19, 2021Date of Patent: December 5, 2023Assignee: EDITAS MEDICINE, INC.Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
-
Patent number: 11826416Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.Type: GrantFiled: July 7, 2021Date of Patent: November 28, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Parinaz Aliahmad, Jason L. Dehart
-
Patent number: 11827668Abstract: The disclosure provides methods for generating an optimized nucleotide sequence encoding an engineered influenza structural protein and the optimized nucleotide sequences obtained therefrom. The optimized nucleotide sequences can be used in a reverse genetics system to facilitate the rescue of infectious influenza virus containing the engineered structural proteins and/or enhance viral titers. Also provided are methods of preparing an influenza vaccine composition using the optimized nucleotide sequences, as well as methods of inducing an immune response using the influenza vaccine composition.Type: GrantFiled: July 19, 2022Date of Patent: November 28, 2023Assignee: SANOFI PASTEUR INC.Inventors: Tod Dwayne Strugnell, Guadalupe Cortes-Garcia, Tim Alefantis
-
Patent number: 11820794Abstract: Disclosed herein include methods, compositions, and kits suitable for robust and tunable control of payload gene expression. Some embodiments provide rationally designed circuits, including miRNA-level and/or protein-level incoherent feed-forward loop circuits, that maintain the expression of a payload at an efficacious level. The circuit can comprise a promoter operably linked to a polynucleotide encoding a fusion protein comprising a payload protein, a protease, and one or more self-cleaving peptide sequences. The payload protein can comprise a degron and a cut site the protease is capable of cutting to expose the degron. The circuit can comprise a promoter operably linked to a polynucleotide comprising a payload gene, a silencer effector cassette, and one or more silencer effector binding sequences.Type: GrantFiled: November 21, 2020Date of Patent: November 21, 2023Assignee: California Institute of TechnologyInventors: Michael J. Flynn, Michael B. Elowitz, Acacia Hori, Viviana Gradinaru
-
Patent number: 11813323Abstract: The invention relates to an immunization regimen whereby an infant is protected against respiratory syncytial virus (RSV) through administration of a first anti-RSV immune response inducing composition to his or her mother during pregnancy, followed by administration of a second anti-RSV immune response inducing composition to the infant after birth.Type: GrantFiled: June 24, 2022Date of Patent: November 14, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Philip Dormitzer
-
Patent number: 11802273Abstract: The disclosure provides for an isolated recombinant influenza virus having at least one of: a PA gene segment encoding PA with a residue at position 443 that is not arginine, a PB1 gene segment encoding PB1 with a residue at position 737 that is not lysine, a PB2 gene segment encoding PB2 with a residue at position 25 that is not valine or a residue at position 712 that is not glutamic acid, a NS gene segment encoding a NS1 with a residue at position 167 that is not proline, a HA gene segment encoding a HA with a residue at position 380 that is not threonine, or any combination thereof, and methods of making and using the virus.Type: GrantFiled: June 21, 2021Date of Patent: October 31, 2023Assignee: Wisconsin Alumni Research Foundation (WARF)Inventors: Yoshihiro Kawaoka, Satoshi Fukuyama, Shinji Watanabe
-
Patent number: 11795478Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.Type: GrantFiled: May 11, 2022Date of Patent: October 24, 2023Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Virginia Ammendola, Stefania Capone, Stefano Colloca, Antonella Folgori, Rossella Merone